IPX066 Demonstrates Efficacy and Safety in ADVANCE-PD Phase III Study in Treatment of Advanced Parkinson’s Disease!
IPX066 met the primary end point, significantly reducing percentage of “off time” over IR CD-LD
Conference call and Webcast presentation scheduled for Tuesday, March 15 at 9:00 a.m. ET(Today)
Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. (NASDAQ:IPXL) is a technology-based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax is headquartered in Hayward, California, and has a full range of capabilities in its Hayward, Philadelphia and Taiwan facilities
IPXL has announced statistically significant, positive, top-line results of the ADVANCE-Parkinson’s Disease (PD) Phase III clinical study of the safety and efficacy of IPX066 versus immediate-release (NYSE:IR) carbidopa-levodopa (CD-LD) in advanced PD patients experiencing motor fluctuations. IPX066 is an investigational extended release (ER) CD-LD product. The ADVANCE-PD results demonstrated that IPX066 produced significantly improved control of motor symptoms as compared to IR CD-LD in multiple clinical measures in subjects with advanced PD.
Read more at: http://crwewallstreet.com/?p=16713